Coronado Biosciences and Burnham Institute for Medical Research Sign Exclusive Worldwide License Agreement to Develop and Commercialize Apogossypol for the Treatment of Cancer

SAN DIEGO, May 30, 2007 (PRIME NEWSWIRE) -- Coronado Biosciences Inc. (Coronado), a privately-held, clinical stage biopharmaceutical company focused on the development of novel and proprietary cancer therapeutics, and Burnham Institute for Medical Research (Burnham), a California-based, non-profit medical research institute, today announced an agreement granting Coronado exclusive worldwide rights to develop and commercialize Apogossypol. Apogossypol is a small molecule that is believed to inhibit key prosurvival proteins from the Bcl-2 family. These proteins are commonly overexpressed in a wide variety of solid tumors and hematological malignancies. It has been demonstrated in preclinical models that the inhibition of these proteins by Apogossypol results in cancer cell apoptosis and reversal of cancer therapy resistance in preclinical models.

Back to news